$SIBN

Maheshwari Anshul sold $337K of SIBN

Maheshwari Anshul (Chief Op & Financial Officer) sold 16,975 shares of SI-BONE, Inc. (SIBN) at an average of $19.86 ($19.55–$20.02, $0.34M total) across 2 trades over 2026-08-19 to 2026-08-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Maheshwari Anshul
Published Aug 21, 2026, 9:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 10:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SIBN
Neutral
medium confidence
Mentioned
$SIBN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SIBNNeutralLow
01

Why it matters

The CFO's sale reduces insider ownership but is unlikely to materially affect control or strategic direction.

02

Market read

Insider sale is a modest, routine disclosure with limited trading relevance.

03

What to watch

Potential upcoming earnings or product announcements that may offset any negative sentiment.

Relevance 3/10Novelty 4/10Timing: filed today

Background

Form 4 filings disclose insider transactions; a 10b5-1 plan indicates pre-arranged sales.

Company-level read

Ticker impact

$SIBNNeutralMedium confidence
Context

Chief Operating & Financial Officer sold 16,975 shares for $337K via a 10b5-1 plan, reducing his stake to 234,920 shares.

Expected impact

Potential short-term downward pressure of 1-2% if market perceives negative sentiment.

Evidence & confidence

CFO insider sales often attract attention; however, the $337K size is small and likely has limited impact on price.

Market effects

Minimal effect on the orthopedic device sector; no broader industry catalyst.

None

None

Counterpoint

The sale could be a routine liquidity event unrelated to company outlook.

Key entities

  • Maheshwari Anshul

    Chief Operating & Financial Officer of SI-BONE, Inc.

  • SI-BONE, Inc.

    Medical device company listed on NASDAQ under ticker SIBN.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SIBNHigh

SI-BONE, Inc. (SIBN): Results of Operations and Financial Condition

SI-BONE, Inc. (SIBN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance Delivered ~15% WW revenue growth and ~178% increase in adjusted EBITDA ~19% increase in U.S. physician base Second Quarter 2026 Financial Highlights (all comparisons are to t